Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population

Pharmacotherapy. 2002 Jun;22(6):701-4. doi: 10.1592/phco.22.9.701.34065.

Abstract

Study objective: To determine the long-term tolerability of prophylactic administration of pyrazinamide and levofloxacin in patients possibly exposed to multidrug-resistant tuberculosis (MDRTB) after undergoing solid organ transplantation.

Design: Retrospective analysis.

Setting: Community outpatient clinic.

Patients: Forty-eight recipients of solid organ transplants beginning prophylaxis for MDRTB during August 1999 after possible exposure to a single index case of multidrug-resistant Mycobacterium tuberculosis within our community

Intervention: Prophylaxis consisted of pyrazinamide 30 mg/kg/day plus levofloxacin 500 mg/day, administered for 1 year.

Measurements and main results: Thirteen (27.1%) of the 48 patients completed therapy; 27 (56.3%) discontinued therapy within 4 months due to adverse drug events. Gastrointestinal intolerance was the major adverse event resulting in early discontinuation.

Conclusion: Prophylaxis of MDRTB with levofloxacin and pyrazinamide was associated with limited tolerability due to the high frequency of adverse events. While we search for a better tolerated prophylactic regimen, close monitoring for adverse reactions is recommended.

MeSH terms

  • Anti-Infective Agents / adverse effects*
  • Anti-Infective Agents / therapeutic use
  • Antitubercular Agents / adverse effects*
  • Antitubercular Agents / therapeutic use
  • Drug Resistance, Microbial
  • Drug Resistance, Multiple
  • Drug Therapy, Combination
  • Female
  • Gastrointestinal Diseases / chemically induced
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Levofloxacin*
  • Male
  • Middle Aged
  • Ofloxacin / adverse effects*
  • Ofloxacin / therapeutic use
  • Organ Transplantation / adverse effects*
  • Pyrazinamide / adverse effects*
  • Pyrazinamide / therapeutic use
  • Retrospective Studies
  • Transplantation Immunology
  • Tuberculosis / microbiology*
  • Tuberculosis / prevention & control*

Substances

  • Anti-Infective Agents
  • Antitubercular Agents
  • Immunosuppressive Agents
  • Pyrazinamide
  • Levofloxacin
  • Ofloxacin